AX-2026-041879
Retatrutide · 30 mg declared · SinoPep Biotechnology (Changzhou) Co., Ltd. · lot SNP-2603-G4042
- Report ID
- AX-2026-041879
- Compound
- Retatrutide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- SinoPep — SinoPep Biotechnology (Changzhou) Co., Ltd.
- Batch / lot
- SNP-2603-G4042
- Declared label claim
- 30mg
- Laboratory
- Janoshik Analytical
- Assay date
- 22 Feb 2026
- Submitted
- 12 Mar 2026
- Quarter
- 2026-Q1
- Submitter
- Contributor #Q-2836
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 97.56 | % area | ≥ 96.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 2.44 | % area | ≤ 3.5 | PASS |
| Largest single impurity | RP-HPLC — [D-Aib2]-diastereomer | 1.58 | % area | ≤ 1.00 | FAIL |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 4728.4871 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 4728.4781 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -1.9 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 87.64 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 85.50 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 34.00 | mg | 30 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 29.070 | mg | 30 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 96.9 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 5.53 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 6.50 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.33 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 4.60 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 20.75 | min | 20.71 ± 0.50 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.10 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 42,816 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Aib2]-diastereomer | 0.54 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Retatrutide — main peak | 20.75 | 4,741,718 | 97.56 | — |
| 2 | [D-Aib2]-diastereomer | 20.53 | 76,793 | 1.58 | 0.000 |
| 3 | truncated (5-39) | 18.83 | 26,732 | 0.55 | -428.201 |
| 4 | des-Aib20 analogue | 20.31 | 9,235 | 0.19 | -85.053 |
| 5 | oxidised Trp (+16 Da) | 20.09 | 3,402 | 0.07 | +15.995 |
| 6 | incomplete Fmoc removal (+222 Da) | 23.16 | 1,458 | 0.03 | +222.068 |
| 7 | retatrutide dimer | 24.87 | 972 | 0.02 | +4728.487 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 4728.4871 Da, computed from C221H342N46O68. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 7+ | 676.5054 | 676.5041 | -0.0013 | 8.0 |
| 6+ | 789.0885 | 789.0870 | -0.0015 | 57.0 |
| 5+ | 946.7047 | 946.7029 | -0.0018 | 100.0 |
| 4+ | 1183.1291 | 1183.1268 | -0.0023 | 56.1 |
| 3+ | 1577.1696 | 1577.1666 | -0.0030 | 7.7 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 5.53 |
| Counter-ion (TFA) | ion chromatography | 6.50 |
| Residual solvent + inorganic residue | estimated | 0.33 |
| Total peptide content | by difference | 87.64 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 97.22 | 97.56 | divergence -0.36 pp vs batch median |
| Total impurities (% area) | 2.78 | 2.44 | |
| Largest single impurity (% area) | 1.23 | 1.58 | |
| Water (%) | 3.6 | 5.53 | |
| Counter-ion (%) | 7.5 | 6.50 | |
| Peptide content (%w/w) | 88.3 | 87.64 | |
| Endotoxin (EU/mg) | 0.84 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (−20 °C, 1 d) → laboratory (courier, dry ice, 11 d) → assay.
- Assay date
- 22 Feb 2026
- Submitted to the index
- 12 Mar 2026
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations 2
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot SNP-2603-G4042 n=12
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041869 | SNP-2603-G4042 | Nordanalyt | 2026-Q1 | 97.62 | 5.52 | 101.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041870 | SNP-2603-G4042 | Janoshik | 2026-Q1 | 97.29 | 5.12 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041871 | SNP-2603-G4042 | Medutest | 2026-Q1 | 97.70 | 5.92 | 103.4 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041872 | SNP-2603-G4042 | Janoshik | 2026-Q1 | 97.75 | 5.33 | 106.2 | Buyer-sourced | 2 | FAIL |
| AX-2026-041873 | SNP-2603-G4042 | Kestrel | 2026-Q1 | 97.96 | 5.06 | 97.2 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041874 | SNP-2603-G4042 | Janoshik | 2026-Q1 | 97.83 | 5.56 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041875 | SNP-2603-G4042 | VendorInvestigate | 2026-Q1 | 97.59 | 5.40 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041876 | SNP-2603-G4042 | Janoshik | 2026-Q1 | 97.52 | 5.79 | 89.8 | Buyer-sourced | 2 | MARGINAL |
| AX-2026-041877 | SNP-2603-G4042 | Janoshik | 2026-Q1 | 97.52 | 5.67 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-041878 | SNP-2603-G4042 | Nordanalyt | 2026-Q1 | 97.42 | 4.84 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041880 | SNP-2603-G4042 | Medutest | 2026-Q1 | 97.44 | 5.22 | — | Buyer-sourced | 1 | MARGINAL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042437 | Homopeptide | HOMO-2605-V4718 | Nordanalyt | 2026-Q3 | 98.68 | 3.67 | 102.8 | Buyer-sourced | 0 | PASS |
| AX-2026-043095 | KP | KP-2607-H5774 | Janoshik | 2026-Q3 | 95.81 | 5.48 | 105.2 | Buyer-sourced | 0 | FAIL |
| AX-2026-042282 | TFC | TFC-2608-J1156 | Janoshik | 2026-Q3 | 98.54 | 4.27 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043094 | KP | KP-2607-H5774 | PeptideMeter | 2026-Q3 | 96.32 | 6.40 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-042441 | Homopeptide | HOMO-2605-V4718 | Medutest | 2026-Q3 | 98.93 | 4.22 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041427 | QYB | QYB-2604-B4920 | PeptideMeter | 2026-Q3 | 97.93 | 2.45 | 101.7 | Buyer-sourced | 0 | PASS |
| AX-2026-041786 | ASY | ASY-{CAT}-2288 | VendorInvestigate | 2026-Q3 | 98.78 | 6.59 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041428 | QYB | QYB-2604-B4920 | Janoshik | 2026-Q3 | 98.35 | 3.20 | — | Laboratory-retained | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041867 | CJC-1295 with DAC | SNP-2607-C3886 | Janoshik | 2026-Q3 | 99.24 | 5.12 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-041913 | Ipamorelin | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 98.88 | 5.28 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-041914 | Ipamorelin | SNP-2606-L4478 | Janoshik | 2026-Q3 | 99.14 | 5.49 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041909 | Ipamorelin | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 99.00 | 5.48 | 89.5 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041895 | Ipamorelin | SNP-2602-B3833 | Janoshik | 2026-Q3 | 99.93 | 4.72 | 105.9 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041930 | IGF-1 LR3 | SNP-2606-D4620 | Medutest | 2026-Q3 | 98.54 | 5.37 | 93.8 | Buyer-sourced | 0 | PASS |
| AX-2026-041898 | Ipamorelin | SNP-2602-B3833 | Nordanalyt | 2026-Q3 | 99.93 | 4.54 | 96.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041931 | IGF-1 LR3 | SNP-2606-D4620 | PeptideMeter | 2026-Q3 | 97.93 | 5.19 | 93.4 | Buyer-sourced | 0 | PASS |